#USA #San Francisco #Caris Life Sciences #Precision Oncology #ASCO GU

Caris Life Sciences to Present at the 2025 ASCO Genitourinary Cancers Symposium

Introduction
Caris Life Sciences®, a pioneer in precision medicine and a leader in next-generation AI TechBio, is set to make a significant impact at the upcoming 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), scheduled for February 13-15 in San Francisco. In collaboration with its Caris Precision Oncology Alliance™ (Caris POA), the company will present key findings from three pivotal studies that delve into prostate cancer and urothelial carcinoma.

Expanding Cancer Insights
Recent innovations from Caris have pushed the boundaries of cancer research. With a commitment to leveraging advanced molecular profiling and extensive databases, the studies aim to enhance understanding and treatment of these cancers. "We are proud to present innovative research for prostate cancer and urothelial carcinoma at the upcoming ASCO GU meeting," remarked Dr. James Hamrick, Chairman of the Caris Precision Oncology Alliance.

The presentations will include insights that could change the paradigm of diagnosis, prognosis, and treatment plans for cancer patients.

Key Studies to be Presented

The three studies, each showcasing different aspects of cancer research, will be available on-site at Caris' booth (#32) during the symposium:
1. Evaluating Molecular Alteration Profiles to Distinguish Intraductal Carcinoma of the Prostate
- Poster Session A | Poster Board L3 | Abstract 407
- Date: February 13; Time: 11:25 a.m. – 12:45 p.m. PST

2. Downregulation of E-selectin and Contributions to Immune Restraining in Prostate Cancer
- Poster Session A | Poster Board G30 | Abstract 257
- Date: February 13; Time: 11:25 a.m. – 12:45 p.m. PST

3. Real-World Analysis of 2IR Immune Response Score in Urothelial Carcinoma (UC)
- Poster Session B | Poster Board D36 | Abstract 739
- Date: February 14; Time: 11:30 a.m. – 12:45 p.m. PST

Collaboration with Cancer Centers
The Caris POA consists of a robust network of 96 cancer centers, academic institutions, and healthcare systems, including 47 NCI-designated cancer centers. Together, they are making strides in advancing precision oncology and biomarker-driven research that improves clinical outcomes for patients. The collaboration focuses on establishing and optimizing the standards of care for molecular testing, which is critical for effective interventions in cancer treatment.

The Vision of Caris Life Sciences
Founded with the mission to realize the potential of precision medicine, Caris Life Sciences is dedicated to revolutionizing healthcare. Utilizing whole exome and whole transcriptome sequencing alongside AI and machine learning, Caris provides unparalleled insights into the molecular complexity of diseases. This comprehensive approach aims at facilitating early detection and the most appropriate treatment paths for patients.

Conclusion
The ASCO GU Symposium serves as a crucial platform for Caris to disseminate vital research and innovations to the global oncology community. As they unveil these significant studies, the potential to reshape patient care in cancer treatment continues to expand. Stay tuned for more insights that could reshape the future of cancer therapy.

For more details, visit Caris Life Sciences.